VEGFA and neoplasm: Lastly, VEGF-A expression is heightened in brain metastases (BMs) compared to gynecologic primary tumors [77], while the active tumor immune microenvironment observed in both primary and metastatic sites supports combining antiangiogenic therapies with immune checkpoint inhibitors for the treatment of EC with BMs [103].